JP2020529996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529996A5 JP2020529996A5 JP2020505487A JP2020505487A JP2020529996A5 JP 2020529996 A5 JP2020529996 A5 JP 2020529996A5 JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020505487 A JP2020505487 A JP 2020505487A JP 2020529996 A5 JP2020529996 A5 JP 2020529996A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- individual
- daily dose
- plasma concentration
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023014110A JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2024192836A JP2025020292A (ja) | 2017-08-04 | 2024-11-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541591P | 2017-08-04 | 2017-08-04 | |
| US62/541,591 | 2017-08-04 | ||
| US201762584537P | 2017-11-10 | 2017-11-10 | |
| US62/584,537 | 2017-11-10 | ||
| US201862639922P | 2018-03-07 | 2018-03-07 | |
| US62/639,922 | 2018-03-07 | ||
| US201862671585P | 2018-05-15 | 2018-05-15 | |
| US62/671,585 | 2018-05-15 | ||
| PCT/US2018/045180 WO2019028360A1 (en) | 2017-08-04 | 2018-08-03 | MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014110A Division JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529996A JP2020529996A (ja) | 2020-10-15 |
| JP2020529996A5 true JP2020529996A5 (enExample) | 2021-10-07 |
Family
ID=63350605
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505487A Pending JP2020529996A (ja) | 2017-08-04 | 2018-08-03 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2023014110A Pending JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2024192836A Pending JP2025020292A (ja) | 2017-08-04 | 2024-11-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023014110A Pending JP2023065372A (ja) | 2017-08-04 | 2023-02-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
| JP2024192836A Pending JP2025020292A (ja) | 2017-08-04 | 2024-11-01 | 肥大型心筋症の治療で使用するためのマバカムテン |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20200054636A1 (enExample) |
| EP (2) | EP3661514B1 (enExample) |
| JP (3) | JP2020529996A (enExample) |
| KR (2) | KR20250116181A (enExample) |
| CN (2) | CN111182901A (enExample) |
| AU (2) | AU2018311974B2 (enExample) |
| CA (1) | CA3071948A1 (enExample) |
| DK (1) | DK3661514T3 (enExample) |
| ES (1) | ES3055679T3 (enExample) |
| FI (1) | FI3661514T3 (enExample) |
| HR (1) | HRP20251598T1 (enExample) |
| HU (1) | HUE073047T2 (enExample) |
| IL (2) | IL322175A (enExample) |
| LT (1) | LT3661514T (enExample) |
| MA (1) | MA49760B1 (enExample) |
| MX (3) | MX2020001406A (enExample) |
| MY (1) | MY208231A (enExample) |
| PL (1) | PL3661514T3 (enExample) |
| PT (1) | PT3661514T (enExample) |
| RS (1) | RS67534B1 (enExample) |
| RU (1) | RU2020109345A (enExample) |
| SG (2) | SG11202000549TA (enExample) |
| SI (1) | SI3661514T1 (enExample) |
| SM (1) | SMT202500413T1 (enExample) |
| TW (1) | TWI907332B (enExample) |
| UA (1) | UA130213C2 (enExample) |
| UY (1) | UY37834A (enExample) |
| WO (1) | WO2019028360A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3740481T3 (ro) | 2018-01-19 | 2025-06-30 | Cytokinetics Inc | Analogi de dihidrobenzofuran și inden în calitate de inhibitori ai sarcomerului cardiac |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| WO2020257609A1 (en) * | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics and treatments for cardiac disease |
| CN110698415B (zh) * | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| WO2021092598A1 (en) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| US20230057197A1 (en) * | 2020-01-28 | 2023-02-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of mavacamten and process for preparation thereof |
| CA3190060A1 (en) * | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| JP2023550444A (ja) | 2020-11-20 | 2023-12-01 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 |
| MX2023008810A (es) * | 2021-02-01 | 2023-08-04 | Dr Reddys Laboratories Ltd | Proceso de preparacion de mavacamten y formas en estado solido del mismo. |
| JP2024508526A (ja) | 2021-03-04 | 2024-02-27 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (en) | 2021-03-12 | 2022-09-15 | Sandoz Ag | Crystalline forms of mavacamten for the treatment of hcm |
| ES3014965T3 (en) | 2021-07-16 | 2025-04-28 | Cytokinetics Inc | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| US20240389972A1 (en) * | 2021-09-24 | 2024-11-28 | Koninklijke Philips N.V. | METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) |
| IL319671A (en) | 2022-09-26 | 2025-05-01 | Edgewise Therapeutics Inc | 4,1-Dihydroquinazolinone compounds and their uses |
| WO2024097284A1 (en) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
| CN121194963A (zh) | 2023-03-27 | 2025-12-23 | 艾知怀斯治疗学公司 | 喹啉酮酰胺类化合物及其用途 |
| EP4688756A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
-
2018
- 2018-08-03 KR KR1020257024814A patent/KR20250116181A/ko active Pending
- 2018-08-03 HR HRP20251598TT patent/HRP20251598T1/hr unknown
- 2018-08-03 MX MX2020001406A patent/MX2020001406A/es unknown
- 2018-08-03 CA CA3071948A patent/CA3071948A1/en active Pending
- 2018-08-03 TW TW107127110A patent/TWI907332B/zh active
- 2018-08-03 SI SI201831270T patent/SI3661514T1/sl unknown
- 2018-08-03 MA MA49760A patent/MA49760B1/fr unknown
- 2018-08-03 KR KR1020207004507A patent/KR20200035973A/ko not_active Ceased
- 2018-08-03 SG SG11202000549TA patent/SG11202000549TA/en unknown
- 2018-08-03 IL IL322175A patent/IL322175A/en unknown
- 2018-08-03 HU HUE18759209A patent/HUE073047T2/hu unknown
- 2018-08-03 SM SM20250413T patent/SMT202500413T1/it unknown
- 2018-08-03 CN CN201880050881.4A patent/CN111182901A/zh active Pending
- 2018-08-03 PT PT187592092T patent/PT3661514T/pt unknown
- 2018-08-03 EP EP18759209.2A patent/EP3661514B1/en active Active
- 2018-08-03 EP EP25196218.9A patent/EP4659806A3/en active Pending
- 2018-08-03 FI FIEP18759209.2T patent/FI3661514T3/fi active
- 2018-08-03 ES ES18759209T patent/ES3055679T3/es active Active
- 2018-08-03 DK DK18759209.2T patent/DK3661514T3/da active
- 2018-08-03 RU RU2020109345A patent/RU2020109345A/ru unknown
- 2018-08-03 PL PL18759209.2T patent/PL3661514T3/pl unknown
- 2018-08-03 IL IL272300A patent/IL272300B2/en unknown
- 2018-08-03 UA UAA202001501A patent/UA130213C2/uk unknown
- 2018-08-03 LT LTEPPCT/US2018/045180T patent/LT3661514T/lt unknown
- 2018-08-03 CN CN202410743651.3A patent/CN118593507A/zh active Pending
- 2018-08-03 JP JP2020505487A patent/JP2020529996A/ja active Pending
- 2018-08-03 MY MYPI2020000493A patent/MY208231A/en unknown
- 2018-08-03 RS RS20251281A patent/RS67534B1/sr unknown
- 2018-08-03 AU AU2018311974A patent/AU2018311974B2/en active Active
- 2018-08-03 WO PCT/US2018/045180 patent/WO2019028360A1/en not_active Ceased
- 2018-08-03 SG SG10202112960QA patent/SG10202112960QA/en unknown
- 2018-08-06 UY UY0001037834A patent/UY37834A/es not_active Application Discontinuation
-
2019
- 2019-03-26 US US16/364,322 patent/US20200054636A1/en not_active Abandoned
-
2020
- 2020-02-04 MX MX2024000348A patent/MX2024000348A/es unknown
- 2020-02-04 MX MX2024008096A patent/MX2024008096A/es unknown
-
2022
- 2022-03-23 US US17/701,863 patent/US20220226324A1/en not_active Abandoned
- 2022-06-16 US US17/842,389 patent/US20220313695A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023014110A patent/JP2023065372A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203872A patent/AU2024203872A1/en active Pending
- 2024-09-06 US US18/827,049 patent/US20240423981A1/en not_active Abandoned
- 2024-11-01 JP JP2024192836A patent/JP2025020292A/ja active Pending
-
2025
- 2025-03-18 US US19/082,967 patent/US20250213565A1/en active Pending
- 2025-08-01 US US19/288,391 patent/US20260007671A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529996A5 (enExample) | ||
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP6309454B2 (ja) | 癌の併用処置 | |
| US8697662B2 (en) | Methods for treating Kaposi sarcoma | |
| RU2020109345A (ru) | Применение мавакамтена для лечения гипертрофической кардиомиопатии | |
| JP6858716B2 (ja) | 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法 | |
| JP2015526458A5 (enExample) | ||
| JP5643213B2 (ja) | 肥大性心筋症治療用のホスホジエステラーゼタイプＩＩＩ（ＰＤＥＩＩＩ）インヒビターまたはＣａ２＋感作剤 | |
| TW202423423A (zh) | 治療非阻塞性肥厚性心肌病之方法 | |
| US20240261242A1 (en) | Methods of intravenously administering sotalol | |
| WO2023009710A1 (en) | Treatment of hfpef in post-menopausal women with an sgc stimulator | |
| CA2753754C (en) | Methods for treating schizophrenia | |
| JP6028983B2 (ja) | ビダラビンによる心房細動治療 | |
| JP7439297B2 (ja) | 肥大型心筋症治療用薬学組成物およびその組成物を用いた治療方法 | |
| TW202539641A (zh) | 用於治療心臟病之方法 | |
| EP4255436A1 (en) | Method of treating hereditary hemorrhagic telangiectasia using pazopanib | |
| Efanov et al. | ARTERIAL HYPERTENSION CONTROL IN THE EXTREME NORTH POPULATION OF THE EMPLOYABLE AGE: PP. 34.397 | |
| Rekovets et al. | INFLUENCE DIFFERENT TYPE OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION (AH) AND METABOLIC SYNDROME (MS) ON INSULIN RESISTANCE DEPENDS ON SEX: PP. 34.398 | |
| RU2022110225A (ru) | Применение мавакамтена для лечения гипертрофической кардиомиопатии | |
| Nikolaeva et al. | Results of the Cardiological Study Invest: A New Word in the Therapy of Patients with Hypertension | |
| M-Castillo et al. | EFFECT OF MANIDIPINE IN CHRONIC KIDNEY DISEASE PATIENTS WITH METABOLIC SYNDROME. PLASENCIA STUDY: PP. 34.399 | |
| Ferrara et al. | HIGH TG/HDL RATIO HELPS IN THE EVALUATION OF CV RISK OF HYPERTENSIVE PATIENTS WITHOUT METABOLIC SYNDROME: PP. 34.400 | |
| JP2005519072A (ja) | 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤 | |
| HK1152878B (en) | Dosing regimen for a selective sip1 receptor agonist | |
| HK1152878A (en) | Dosing regimen for a selective sip1 receptor agonist |